INSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INSP is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near resistance in pre-market, but the broader setup is still mixed: short-term momentum is improving, yet the longer-term trend remains bearish and analysts are cutting targets on weak near-term visibility. If you are impatient and want a clear buy decision today, this is not the best entry. I would hold off and wait for either a cleaner technical breakout above resistance or more clarity from earnings and reimbursement trends.
Pre-market price is 56.15, essentially flat, with the stock sitting just above the pivot at 55.159 and below first resistance at 57.795. MACD is positive and expanding, which supports short-term upside momentum, but RSI at 56.04 is only neutral. The moving averages are still bearish (SMA_200 > SMA_20 > SMA_5), so the larger trend has not fully reversed. The near-term setup is constructive, but not strong enough to call it a decisive buy yet.
["Q4 2025 revenue grew 12.25% YoY to 269.1M.", "Net income and EPS surged sharply year over year, showing strong profitability improvement.", "Gross margin remained very high at 86.59%.", "CMS updates on HGNS C-codes were described by some analysts as directionally positive and helped reduce some reimbursement downside risk.", "Bullish options positioning with low put-call open interest ratio."]
["Analysts repeatedly cut price targets in April, reflecting weaker near-term confidence.", "Truist and RBC both highlighted reimbursement friction, coding headwinds, and limited visibility for the next couple of quarters.", "News flow points to shareholder governance concerns tied to weaker-than-expected demand for Inspire V.", "The stock remains in a bearish moving-average structure.", "Earnings are due on 2026-05-04 after hours, and the market is likely focused on guidance risk."]
In Q4 2025, Inspire Medical posted solid top-line and bottom-line growth. Revenue rose 12.25% year over year to 269.1M, net income increased 286.36% to 136.1M, EPS climbed 301.72% to 4.66, and gross margin improved to 86.59%. The latest quarter season is Q4 2025, and the financials show strong reported profitability and healthy margins. The main issue is not the latest quarter itself, but the market's concern that near-term growth may slow due to reimbursement and coding-related pressures.
The analyst trend has turned more cautious recently. Multiple firms lowered price targets in April: RBC cut to 56 and kept Sector Perform, Truist cut to 64 and kept Hold, Mizuho cut to 70 and kept Outperform, Stifel cut to 70 and kept Buy, and Evercore cut to 62 and kept Outperform. Morgan Stanley also slashed its target to 60 and kept Equal Weight, while UBS cut to 67 and stayed Neutral. Wall Street is split, but the tone is clearly cautious overall: the bullish camp still sees long-term upside, while the bearish/neutral camp is focused on reimbursement friction, slowing domestic growth, and limited near-term visibility. There is no evidence here of strong fresh insider or political buying support; trading trends show hedge funds and insiders are neutral, and there is no recent congress trading data.
